8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Mar 5, 2026·SEC
Contineum Therapeutics, Inc. Class A Common Stock(CTNM)Earnings, Financials & Key Ratios
CTNM•NASDAQ
Price updated Jun 11, 2026
AboutContineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Show more
- Revenue$0
- EBITDA-$68M-33.8%
- Net Income-$60M-41.9%
- EPS (Diluted)-2.17-33.1%
- ROE-26.13%+59.8%
- ROIC-27.15%-3.9%
- Debt/Equity0.03
CTNM Key Insights
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Healthy 5Y average net margin of 45.4%
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CTNM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CTNM Price & Volume
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) stock price & volume — 10-year historical chart
Loading chart...
CTNM Growth Metrics
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-17.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1.04%
Return on Capital
10 Years-32.67%
5 Years-32.67%
3 Years-26.39%
Last Year-28.98%
CTNM Recent Earnings
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (44%)
Q2 2026Latest
May 5, 2026EPS
$0.39
Est $0.55
+29.1%
Revenue
—
Q2 2026
Mar 5, 2026EPS
$0.49
Est $0.50
+2.0%
Revenue
—
Est $8M
Q4 2025
Oct 30, 2025EPS
$0.45
Est $0.58
+22.4%
Revenue
—
Est $5M
Q3 2025
Aug 5, 2025EPS
$0.62
Est $0.56
-10.7%
Revenue
—
Est $8M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.39vs $0.55+29.1% | — |
| Q2 2026 | Mar 5, 2026 | $0.49vs $0.50+2.0% | —vs $8M |
| Q4 2025 | Oct 30, 2025 | $0.45vs $0.58+22.4% | —vs $5M |
| Q3 2025 | Aug 5, 2025 | $0.62vs $0.56-10.7% | —vs $8M |
Based on last 12 quarters of dataView full earnings history →
CTNM Peer Comparison
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 PRTA | 432.44M | 8.26 | -1.82 | -92.84% | -260.92% | -49.88% | 0.05 | |
 ARQT | 3.08B | 24.59 | -189.15 | 91.34% | -0.57% | -1.41% | 0.03 | |
 KYMR | 6.77B | 82.96 | -22.48 | -16.72% | -6.12% | -25.02% | 0.05 | |
 TERN | 4.77B | 52.95 | -51.41 | -20.02% | 0.00 | |||
 ACAD | 3.66B | 21.39 | 9.34 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.66B | 22.44 | 6.80 | 18.52% | 118.91% | 47.59% | 0.23 | |
 PTGX | 7.06B | 109.79 | -53.56 | -89.41% | -6.48% | -17.76% | 0.02 |
Compare CTNM vs Peers
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CTNM Income Statement
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 50M | 0 | 0 | 0 |
Revenue Growth % | - | - | - | -100% | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 258K | 0 | 79K |
COGS % of Revenue | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 50M▲ 0% | -258K▼ 100.5% | 0▲ 100.0% | -79K▲ 0% |
Gross Margin % | - | - | 100% | - | - | - |
Gross Profit Growth % | - | - | - | -100.52% | 100% | - |
Operating Expenses | 28.65M | 22.72M | 66.08M | 50.64M | 68.06M | 66.77M |
OpEx % of Revenue | - | - | 132.15% | - | - | - |
Selling, General & Admin | 6.29M | 5.83M | 6.32M | 12.47M | 16.54M | 17.39M |
SG&A % of Revenue | - | - | 12.64% | - | - | - |
Research & Development | 22.36M | 16.89M | 27.6M | 38.16M | 51.52M | 49.38M |
R&D % of Revenue | - | - | 55.21% | - | - | - |
Other Operating Expenses | -91K | 0 | 32.15M | 0 | 0 | 0 |
Operating Income | -28.65M▲ 0% | -22.72M▲ 20.7% | -16.08M▲ 29.2% | -50.89M▼ 216.6% | -68.06M▼ 33.7% | -66.85M▲ 0% |
Operating Margin % | - | - | -32.15% | - | - | - |
Operating Income Growth % | - | 20.69% | 29.24% | -216.56% | -33.73% | - |
EBITDA | -28.32M | -22.39M | -15.88M | -50.64M | -67.74M | -66.53M |
EBITDA Margin % | - | - | -31.76% | - | - | - |
EBITDA Growth % | - | 20.94% | 29.07% | -218.83% | -33.77% | -254.75% |
D&A (Non-Cash Add-back) | 325K | 329K | 195K | 258K | 323K | 328K |
EBIT | -28.67M | -23.86M | 23.38M | -42.26M | -68.06M | -64.99M |
Net Interest Income | -255K | 373K | 4.4M | 8.9M | 8.25M | 8.5M |
Interest Income | 77K | 761K | 4.61M | 8.9M | 8.25M | 8.5M |
Interest Expense | 332K | 388K | 208K | 0 | 0 | 0 |
Other Income/Expense | -354K | -1.53M | 39.25M | 8.64M | 8.08M | 8.41M |
Pretax Income | -29M▲ 0% | -24.25M▲ 16.4% | 23.17M▲ 195.5% | -42.26M▼ 282.4% | -59.98M▼ 41.9% | -58.44M▲ 0% |
Pretax Margin % | - | - | 46.34% | - | - | - |
Income Tax | 0 | 0 | 450K | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 1.94% | 0% | 0% | 0% |
Net Income | -29M▲ 0% | -24.25M▲ 16.4% | 22.72M▲ 193.7% | -42.26M▼ 286.0% | -59.98M▼ 41.9% | -58.44M▲ 0% |
Net Margin % | - | - | 45.44% | - | - | - |
Net Income Growth % | - | 16.37% | 193.68% | -285.99% | -41.93% | -17.28% |
Net Income (Continuing) | -29M | -24.25M | 22.72M | -42.26M | -59.98M | -58.44M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.15▲ 0% | -0.97▲ 15.7% | 0.13▲ 113.4% | -1.63▼ 1353.8% | -2.17▼ 33.1% | -1.57▲ 0% |
EPS Growth % | - | 15.65% | 113.4% | -1353.85% | -33.13% | -1.04% |
EPS (Basic) | -1.15 | -0.97 | 0.13 | -1.63 | -2.17 | - |
Diluted Shares Outstanding | 25.13M | 25.13M | 25.13M | 25.85M | 27.7M | 37.34M |
Basic Shares Outstanding | 25.13M | 25.13M | 25.13M | 25.85M | 27.7M | 37.34M |
Dividend Payout Ratio | - | - | - | - | - | - |
CTNM Balance Sheet
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Total Current Assets | 69.78M | 48.39M | 127.71M | 206.39M | 267.92M | 252.96M |
Cash & Short-Term Investments | 69M | 47.24M | 125.19M | 204.76M | 262.9M | 246.33M |
Cash Only | 4.63M | 5.57M | 15.53M | 21.94M | 75.6M | 20.16M |
Short-Term Investments | 64.37M | 41.67M | 109.66M | 182.82M | 187.29M | 226.17M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 2.52M | 1.63M | 5.02M | 6.64M |
Total Non-Current Assets | 739K | 2.24M | 2.68M | 6.46M | 8.72M | 8.38M |
Property, Plant & Equipment | 642K | 2.12M | 1.4M | 6.46M | 8.47M | 8.07M |
Fixed Asset Turnover | - | - | 35.79x | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 97K | 129K | 1.28M | 3K | 256K | 312K |
Total Assets | 70.52M▲ 0% | 50.64M▼ 28.2% | 130.39M▲ 157.5% | 212.85M▲ 63.2% | 276.64M▲ 30.0% | 261.35M▲ 0% |
Asset Turnover | - | - | 0.38x | - | - | 0.00x |
Asset Growth % | - | -28.19% | 157.5% | 63.24% | 29.97% | 32.75% |
Total Current Liabilities | 3.67M | 7.55M | 5.48M | 9.97M | 9.74M | 6.66M |
Accounts Payable | 660K | 430K | 635K | 1.81M | 1.02M | 1.5M |
Days Payables Outstanding | - | - | - | 2.56K | - | 6.12K |
Short-Term Debt | 1.25M | 3.95M | 0 | 0 | 2.34M | 2.3M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 79K | 0 | 2.48M | 3.37M | 6.39M | 2.86M |
Current Ratio | 18.99x | 6.41x | 23.29x | 20.69x | 27.50x | 38.00x |
Quick Ratio | 18.99x | 6.41x | 23.29x | 20.69x | 27.50x | 38.00x |
Cash Conversion Cycle | - | - | - | - | - | - |
Total Non-Current Liabilities | 5.26M | 3.82M | 192.84M | 4.81M | 5.91M | 4.65M |
Long-Term Debt | 3.66M | 0 | 192.62M | 0 | 5.91M | 4.65M |
Capital Lease Obligations | 0 | 791K | 108K | 4.81M | 0 | 4.28M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.6M | 3.02M | 110K | 0 | 0 | 0 |
Total Liabilities | 8.93M | 11.37M | 198.32M | 14.78M | 15.65M | 11.31M |
Total Debt | 4.91M | 5.85M | 193.19M | 6.26M | 8.25M | 6.95M |
Net Debt | 279K | 280K | 177.67M | -15.68M | -67.35M | -13.2M |
Debt / Equity | 0.08x | 0.15x | - | 0.03x | 0.03x | 0.03x |
Debt / EBITDA | - | - | - | - | - | -0.10x |
Net Debt / EBITDA | - | - | - | - | - | 0.20x |
Interest Coverage | -86.35x | -61.51x | 112.39x | - | - | - |
Total Equity | 61.59M▲ 0% | 39.27M▼ 36.2% | -67.94M▼ 273.0% | 198.07M▲ 391.5% | 260.99M▲ 31.8% | 250.04M▲ 0% |
Equity Growth % | - | -36.24% | -273% | 391.55% | 31.77% | 31.74% |
Book Value per Share | 2.45 | 1.56 | -2.70 | 7.66 | 9.42 | 6.70 |
Total Shareholders' Equity | 61.59M | 39.27M | -67.94M | 198.07M | 260.99M | 250.04M |
Common Stock | 12K | 12K | 2K | 26K | 37K | 37K |
Retained Earnings | -73.61M | -97.86M | -75.14M | -117.4M | -177.38M | -191.84M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -35K | -76K | 108K | 71K | 260K | -253K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
CTNM Cash Flow Statement
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | -26.27M | -20.12M | 19.35M | -32.84M | -55.31M | -57.17M |
Operating CF Margin % | - | - | 38.7% | - | - | - |
Operating CF Growth % | - | 23.4% | 196.16% | -269.75% | -68.4% | -225.77% |
Net Income | -29M | -24.25M | 22.72M | -42.26M | -59.98M | -58.44M |
Depreciation & Amortization | 325K | 329K | 195K | 258K | 323K | 328K |
Stock-Based Compensation | 1.75M | 1.93M | 2.22M | 6.8M | 10.04M | 11.29M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 553K | 3.14M | -4.76M | -2.98M | 344K | 562K |
Working Capital Changes | 108K | -1.27M | -1.02M | 5.33M | -6.04M | -10.9M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -110K | -230K | 0 | 1.14M | -869K | -2.21M |
Cash from Investing | -64.97M | 22.3M | -65.57M | -69.74M | -3.71M | -57.94M |
Capital Expenditures | -168K | -118K | -414K | -514K | -231K | -496K |
CapEx % of Revenue | - | - | 0.83% | - | - | - |
Acquisitions | 0 | 0 | 0 | 20K | 0 | 0 |
Investments | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 79.84M | -1.24M | 56.18M | 109M | 112.69M | 112.79M |
Debt Issued (Net) | 0 | -1.25M | -3.75M | 0 | 0 | 0 |
Equity Issued (Net) | 79.73M | -4K | 60.11M | 108.21M | 112.69M | 112.69M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -4K | -28K | 0 | 0 | 0 |
Other Financing | 113K | 15K | -184K | 790K | 0 | 104K |
Net Change in Cash | -11.39M▲ 0% | 939K▲ 108.2% | 9.96M▲ 960.4% | 6.42M▼ 35.6% | 53.66M▲ 736.2% | -2.31M▲ 0% |
Free Cash Flow | -26.43M▲ 0% | -20.24M▲ 23.4% | 18.93M▲ 193.6% | -33.36M▼ 276.2% | -55.54M▼ 66.5% | -57.66M▲ 0% |
FCF Margin % | - | - | 37.87% | - | - | - |
FCF Growth % | - | 23.44% | 193.56% | -276.18% | -66.5% | -45.77% |
FCF per Share | -1.05 | -0.81 | 0.75 | -1.29 | -2.01 | -1.54 |
FCF Conversion (FCF/Net Income) | 0.91x | 0.83x | 0.85x | 0.78x | 0.92x | 0.99x |
Interest Paid | 222K | 225K | 150K | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 450K | 0 | 0 | 0 |
CTNM Key Ratios
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -48.09% | - | -64.95% | -26.13% | -27.09% |
| Return on Invested Capital (ROIC) | -33.6% | -16.15% | -26.13% | -27.15% | -27.47% |
| Gross Margin | - | 100% | - | - | - |
| Net Margin | - | 45.44% | - | - | - |
| Debt / Equity | 0.15x | - | 0.03x | 0.03x | 0.03x |
| Interest Coverage | -61.51x | 112.39x | - | - | - |
| FCF Conversion | 0.83x | 0.85x | 0.78x | 0.92x | 0.99x |
| Revenue Growth | - | - | -100% | - | - |
Related:CTNM Dividend History·CTNM Revenue History·CTNM Price History·CTNM P/E History·CTNM Financial Ratios·CTNM Institutional Holders
CTNM SEC Filings & Documents
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) SEC filings — annual & quarterly reports (10-K, 10-Q)
CTNM Frequently Asked Questions
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) grew revenue by 0.0% over the past year. Growth has been modest.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) reported a net loss of $58.4M for fiscal year 2025.
Dividend & Returns
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a return on equity (ROE) of -26.1%. Negative ROE indicates the company is unprofitable.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) had negative free cash flow of $57.7M in fiscal year 2025, likely due to heavy capital investments.